Medipost's Cartistem® Meets All Primary And Secondary Endpoints In Japan Phase 3 Trial And Demonstrates Statistically Significant Efficacy Gains Versus Active Control

Medipost Co Ltd KRX:078160:

• MEDIPOST'S CARTISTEM® MEETS ALL PRIMARY AND SECONDARY ENDPOINTS IN JAPAN PHASE 3 TRIAL AND DEMONSTRATES STATISTICALLY SIGNIFICANT EFFICACY GAINS VERSUS ACTIVE CONTROL

• MEDIPOST CO LTD - JAPAN BIOLOGICS LICENSE APPLICATION FOR CARTISTEM SCHEDULED FOR 2H 2026

• MEDIPOST CO LTD - CARTISTEM MAINTAINS EXCELLENT SAFETY PROFILE IN JAPAN PHASE 3 TRIAL

• MEDIPOST CO LTD - TO SUBMIT JAPAN MARKETING AUTHORIZATION APPLICATION IN 2026, TARGETS REGULATORY APPROVAL BY END 2027

• MEDIPOST CO LTD - CARTISTEM ACHIEVES STATISTICAL SIGNIFICANCE VERSUS STANDARD-OF-CARE IN 52-WEEK JAPAN STUDY